Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429461 | 0.87 | POLB (0.70) | TDP1POLBPKMMITFALDH1A1 | |
| SCHEMBL6429493 | 0.84 | ALDH1A1 (0.60) | TDP1POLBPKMMITFALDH1A1 | |
| SCHEMBL6427583 | 0.79 | POLB (0.74) | TDP1POLBPKMMITFALDH1A1 | |
| SCHEMBL6428110 | 0.78 | MEN1 (0.59) | TDP1POLBPKMALDH1A1GAA | |
| SCHEMBL6429133 | 0.77 | POLB (0.71) | TDP1POLBPKMMITFALDH1A1 | |
| SCHEMBL6427163 | 0.75 | ALDH1A1 (0.62) | TDP1POLBPKMALDH1A1KMT2A | |
| SCHEMBL12443384 | 0.75 | ALDH1A1 (0.62) | TDP1POLBPKMALDH1A1KDM4E | |
| SCHEMBL6428095 | 0.74 | ALDH1A1 (0.61) | ALDH1A1 | |
| SCHEMBL6427991 | 0.73 | MITF (0.64) | TDP1POLBPKMMITFALDH1A1 | |
| SCHEMBL6429606 | 0.73 | ALDH1A1 (0.56) | TDP1POLBPKMALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222408-A1 | Heterocyclic amides with anti-tuberculosis activity | TST, KAT5, NDUFS5 | TDP1 4560/4885POLB 2506/4885PKM 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.